CAMP4 Therapeutics (CAMP) and The Competition Head-To-Head Analysis

CAMP4 Therapeutics (NASDAQ:CAMP) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare CAMP4 Therapeutics to similar companies based on the strength of its risk, profitability, valuation, earnings, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares CAMP4 Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,276.33%	-182.39%	-74.87%
CAMP4 Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Institutional & Insider Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CAMP4 Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1	1	8	1	2.82
CAMP4 Therapeutics Competitors	9874	15294	45656	1600	2.54

CAMP4 Therapeutics currently has a consensus target price of $10.44, indicating a potential upside of 168.49%. As a group, “Biotechnology” companies have a potential upside of 126.06%. Given CAMP4 Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe CAMP4 Therapeutics is more favorable than its peers.

Volatility & Risk

CAMP4 Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, CAMP4 Therapeutics’ peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Earnings and Valuation

This table compares CAMP4 Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50 million	-$80.40 million	-1.82
CAMP4 Therapeutics Competitors	$702.34 million	$9.48 million	-18.82

CAMP4 Therapeutics’ peers have higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

CAMP4 Therapeutics beats its peers on 9 of the 13 factors compared.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.